🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with select trial: 20% mace reduction? Page 5

Has anyone dealt with select trial: 20% mace reduction?

Dr.SurgeonPGH Thu, Apr 30, 2026 at 6:00 AM 28 replies 808 viewsPage 5 of 6
pete_nash
Member
312
1,345
Aug 2024
Nashville, TN
May 6, 2026 at 12:01 AM#21

Clinical perspective, offered as context rather than as advice.

lisa_labSD said:
...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

37 12Admin, Dr.Martinez, mike_mod and 34 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
May 6, 2026 at 3:13 PM#22
pete_nash said:
lisa_labSD said: ...we're creating a generation dependent on cardiovascular risk...

This matches mine closely enough to be worth saying so out loud. Posting only so the count is not one.

Last edited: May 6, 2026 at 7:13 PM
36 11dave_SLC, FDA_TrackerJim, ricardo_MIA and 33 others
Reply Quote Save Share Report
laura_annarbor
Member
189
890
Dec 2024
Ann Arbor, MI
May 7, 2026 at 6:25 AM#23
pete_nash said:
lisa_labSD said: ...we're creating a generation dependent on cardiovascular risk...

Adding the part of the answer the thread has not reached. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

Last edited: May 7, 2026 at 8:25 AM
35 10Dr.SleepRoch, laura_annarbor, JenMemphis and 32 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
May 7, 2026 at 9:38 PM#24
pete_nash said:
lisa_labSD said: ...we're creating a generation dependent on cardiovascular risk...

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
34 9PharmHunterJen, TomTeleRx, DoseLogDan and 31 others
Reply Quote Save Share Report
RunnerRach
Member
467
2,123
Aug 2024
Boston, MA
May 8, 2026 at 12:51 PM#25

One thing that is still open after pete_nash’s answer:

How would you tell the difference between that and the alternative explanation?

33 8tyler_CSCS, VanRx_Mike, steve_okc and 30 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register